These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6443863)

  • 21. [Immunochemical analysis and protective properties of components of Pseudomonas aeruginosa mucus with different molecular weights].
    Zaĭdner IG; Palkina NA; Stanislavskiĭ ES; Landsman NM
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Apr; (4):92-7. PubMed ID: 6791415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the detoxification of Pseudomonas aeruginosa exotoxin.
    Abe C; Takeshi K; Homma JY; Kato I
    Jpn J Med Sci Biol; 1979 Apr; 32(2):88-90. PubMed ID: 120456
    [No Abstract]   [Full Text] [Related]  

  • 23. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice.
    Sokalska M; Maresz-Babczyszyn J
    Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immune anti-Pseudomonas aeruginosa blood preparations (a review of the literature)].
    Nazarchuk LV
    Lik Sprava; 1992 Feb; (2):15-20. PubMed ID: 1441322
    [No Abstract]   [Full Text] [Related]  

  • 25. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 27. [Problems of the immunoprophylaxis of experimental Pseudomonas pyocyanea wound sepsis].
    Kolker II; Stanislavskiĭ ES; Grishina IA
    Zh Mikrobiol Epidemiol Immunobiol; 1979 May; (5):67-72. PubMed ID: 110018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of immunological preparations and their use for preventing and treating pyocyanic infection in burn patients].
    Kolker II; Stanislavskiĭ ES; Grishina IA; Panova IuM; Krokhina MA
    Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):29-33. PubMed ID: 6784114
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunochemical study of a strain of Pseudomonas aeruginosa].
    Stefanini AM; Frigerio M
    Rev Latinoam Microbiol; 1981; 23(2):103-7. PubMed ID: 6798663
    [No Abstract]   [Full Text] [Related]  

  • 31. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.
    Worgall S; Kikuchi T; Singh R; Martushova K; Lande L; Crystal RG
    Infect Immun; 2001 Jul; 69(7):4521-7. PubMed ID: 11401995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.
    Meitert E; Meitert T; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):105-14. PubMed ID: 6816188
    [No Abstract]   [Full Text] [Related]  

  • 33. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
    Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T
    J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of exoenzymes and exotoxin in the pathogenicity of Pseudomonas aeruginosa and the development of a new vaccine.
    Homma JY
    Jpn J Exp Med; 1980 Jun; 50(3):149-65. PubMed ID: 6776324
    [No Abstract]   [Full Text] [Related]  

  • 35. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Pseudomonas antigen by counterimmunoelectrophoresis.
    Adams MB; Aguilar-Torres FG; Rytel MW
    Surg Forum; 1976; 27(62):3-5. PubMed ID: 828314
    [No Abstract]   [Full Text] [Related]  

  • 37. Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice.
    Ohama M; Hiramatsu K; Miyajima Y; Kishi K; Nasu M; Kadota J
    FEMS Immunol Med Microbiol; 2006 Jun; 47(1):107-15. PubMed ID: 16706793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effects of a multi-component vaccine and a formalin-killed cell vaccine on protection against enzootic of hemorrhagic pneumonia due to Pseudomonas aeruginosa in mink.
    Abe C; Homma JY; Noda H; Yanagawa R; Morihara K; Tsuzuki H; Takeuchi S
    Zentralbl Bakteriol A; 1981 Aug; 249(3):413-7. PubMed ID: 6791409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutical pseudomonas aeruginosa antisera. Preparation, control and administration.
    Meitert T; Meitert E; Szegli G; Peligrad I
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):115-21. PubMed ID: 6816189
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.